The preclinical data from our study as well as from previous studies from others may provide explanation that to date, the published case reports of treatment response in cancer patients with MET exon 14 skipping were with MET-targeting small molecule kinase inhibitors, and not with MET-targeting antibody. The gene discussed is MET; the disease is cancer.